Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
Zacks Investment Research | Nov 01, 2018 12:14AM ET
TransEnterix, Inc. (NYSE:TRXC) is scheduled to report third-quarter 2018 results on Nov 8, after the market closes.
In the last reported quarter, the company’s loss per share of 6 cents was in line with the Zacks Consensus Estimate. It witnessed negative surprises in two of the trailing four quarters, the average miss being 138.1%.
Let’s see, how things are shaping up prior to this announcement.
Factors at Play
TransEnterix is expected to make a strong top-line contribution in the third quarter from its several new product developments within the company’score Senhance Surgical System line. Among the resent developments, in the third quarter, the company gained an FDA approval for its additional 5 millimeter Senhance System instruments. This apart, it has received CE Mark approval for its Senhance Ultrasonic Instrument System. In this regard, the company has also filed a FDA 510(k) submission for its Senhance Ultrasonic Instrument System.
TransEnterix, Inc. Price and Consensus
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.